KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China

Virol Sin. 2018 Aug;33(4):369-372. doi: 10.1007/s12250-018-0042-1. Epub 2018 Jul 23.

Authors

Song Hu¹, Fahu Yuan¹, Lingyan Feng¹, Fang Zheng², Feili Gong², Hanju Huang³, Binlian Sun⁴

Affiliations

¹ Medical College, Jianghan University, Wuhan, 430056, China.
² Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
³ Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
⁴ Medical College, Jianghan University, Wuhan, 430056, China. binlian17@jhun.edu.cn.

No abstract available

Publication types

Letter

MeSH terms

Adult
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
China
Drug Therapy, Combination
Female
Gene Frequency
Genetic Association Studies
Genetic Predisposition to Disease
Hepacivirus / drug effects
Hepatitis C, Chronic / blood
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / genetics*
Humans
Interferon-alpha / pharmacology
Interferon-alpha / therapeutic use*
Male
Middle Aged
Polyethylene Glycols / pharmacology
Polyethylene Glycols / therapeutic use*
Receptors, KIR2DL2 / genetics*
Ribavirin / pharmacology
Ribavirin / therapeutic use*
Risk Factors
Treatment Outcome

Substances

Antiviral Agents
Interferon-alpha
KIR2DL2 protein, human
PEG-IFN-SA
Receptors, KIR2DL2
Polyethylene Glycols
Ribavirin